Company / Interest Expense
Theravance Biopharma, Inc. Interest Expense History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$2.4M
FY2023
5-year range
$2.4M / $8.5M
FY2019-FY2023
Trend
-72.5%
vs FY2022
Sector context
#36 of 44
Health Care
What the data says
Theravance Biopharma, Inc.'s interest expense of $2M is lower than 82% of companies in the Health Care sector (FY2023). Improved from $9M to $2M over the past 2 years.
Based on SEC 10-K filings.
$2M in FY2023 with a 5-year CAGR of +10.9%.
Improved from $9M to $2M over the past 2 years.
Health Care sector context is included.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -35.0%
- 5-Year CAGR
- +10.9%
- 10-Year CAGR
- -
Sector benchmark
Top 18% in Health CareTop 18% of 44This company $2.4M Sector average $291.0M
▼
-99.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +10.9%, indicating consistent growth.
- In FY2023, interest expense decreased 72.5% year-over-year.
- Ranks #36 out of 44 companies in the Health Care sector.
- Peak interest expense was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $2.4M | -72.5% |
| FY2022 | $8.5M | +0.0% |
| FY2021 | $8.5M | +0.0% |
| FY2020 | $8.5M | +0.0% |
| FY2019 | $8.5M | +508.8% |
| FY2018 | $1.4M | -83.6% |
| FY2017 | $8.5M | +508.8% |
| FY2016 | $1.4M | - |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026